PLIANT THERAPEUTICS, INC. (PLRX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net unrealized loss on short-term investments | -160 | 1,465 | -128 | |
| Research and development | 32,198 | 47,754 | 45,617 | |
| General and administrative | 13,394 | 14,260 | 15,022 | |
| Total operating expenses | 45,592 | 62,014 | 60,639 | |
| Loss from operations | -45,592 | -62,014 | -60,639 | |
| Interest expense | 809 | 877 | 868 | |
| Interest and other income (expense), net | 3,101 | 5,128 | 5,653 | |
| Net loss | -43,300 | -57,763 | -55,854 | |
| Comprehensive loss | -43,460 | -56,298 | -55,982 | |
| Net loss per share - basic (usd per share) | -0.71 | -0.95 | -0.92 | |
| Net loss per share - diluted (usd per share) | -0.71 | -0.95 | -0.92 | |
| Shares used in computing net loss per share - basic (in shares) | 61,386,183 | 60,730,935 | 60,382,796 | |
| Shares used in computing net loss per share - diluted (in shares) | 61,386,183 | 60,730,935 | 60,382,796 | |